NexGen GxP AI is the only audit-ready agentic platform for validated AI in pharmaceutical manufacturing — purpose-built to support FDA PCCP compliance and EU AI Act Annex III validation. In April 2026, FDA issued its first Warning Letter citing AI misuse in GMP manufacturing. The companies that deploy validated AI first set the standard. NexGen is how you get there: mandatory HITL oversight, PCCP-supporting IQ/OQ documentation, and Annex III compliance evidence.
Pharma leaders want AI. Regulators expect it. But deploying AI in GxP manufacturing without a validated, audit-ready framework creates enforcement exposure — and that window is closing.
Every company deploying AI in regulated manufacturing is re-inventing the compliance framework from scratch. IQ/OQ/PQ for AI is undefined in most quality systems. Change control for model updates, HITL gate design, drift monitoring protocols — these require specialized expertise that does not exist inside most pharma quality teams. The result: AI projects stall, or launch without proper validation.
FDA issued its first Warning Letter citing AI misuse in GMP manufacturing in April 2026 (Purolea, MARCS-CMS 722591). FDA's stated standard: all AI outputs in manufacturing require Quality Unit review. FDA PCCP guidance is final. EU AI Act Annex III enforcement arrives December 2, 2027. Every company using AI without a documented HITL gate now has active enforcement exposure.
Generic AI platforms are unvalidated, have no HITL gate, and create exactly the enforcement exposure FDA just acted on. QMS vendors handle documents — not AI. Consultants charge for time, not outcomes. No vendor delivers a purpose-built AI validation platform with mandatory HITL oversight, IQ/OQ documentation, change control, and EU AI Act Annex III evidence. The market is structurally underserved.
NexGen validates AI systems for GxP environments — any AI, any use case, any regulatory market. We designed our validation framework from the regulatory requirements inward. Every architectural decision is traceable to a specific FDA, EMA, or PIC/S requirement.
Our AI-extended V-model includes pre-built IQ/OQ/PQ templates, AI Performance Requirements specifications, and Ongoing Performance Monitoring protocols — built around FDA CSA, Annex 11, and PIC/S from the ground up.
Every agent action touching a GxP record generates a complete, immutable audit entry. Every decision is traceable. Every change is assessed for regulatory impact. Every human gate is enforced.
// Audit trail entry — batch release AI
agentId: "nexgen-release-v2.1.4"
decision: "RELEASE — Batch 24-1103A"
rationale: "All 14 CPPs within spec"
inputHash: "sha256:a3f8c2..."
confidence: 0.9983
humanReview: true
timestamp: "2026-03-30T14:22:07Z"
Our validated agentic architecture is built to extend across the GxP manufacturing lifecycle — one compliance foundation, multiple validated applications.
AI-assisted review of Batch Manufacturing Records, OOS investigations, deviation reports, and CAPA closures — with mandatory HITL gate, full audit trail, and PCCP-supporting IQ/OQ documentation.
Automated out-of-specification detection with validated root-cause analysis assist, CAPA linkage, and real-time SPC monitoring across production lines.
Validated AI modules for MES workflow orchestration, LIMS data interpretation, clinical supply planning, and supplier quality management — all on the same audit-ready infrastructure.
Our platform is designed against the specific requirements of the frameworks your quality team already knows — not adapted after the fact.
| Capability | NexGen GxP AI | Generic AI Vendors | Traditional Consultants |
|---|---|---|---|
| Pre-built validation templates (IQ/OQ/PQ) | ✓ Core | ✗ | ✗ |
| Audit-ready architecture from day one | ✓ Core | ✗ | Months to build |
| Agentic AI expertise | ✓ Core | Partial | Rare |
| 21 CFR Part 11 / Annex 11 native | ✓ Mapped by design | ✗ | Partial |
| Mandatory HITL gate (21 CFR 211.22(c)) | ✓ Enforced | ✗ | ✗ |
| PCCP-supporting IQ/OQ documentation | ✓ Included | ✗ | ✗ |
| Continuous drift monitoring | ✓ Built-in SPC | Partial | ✗ |
| AI change control automation | ✓ Automated | ✗ | Manual |
| Cell therapy / biologics focus | ✓ Specialized | Generic | Generalist |
We offer a focused technical briefing for quality and operations leadership — no sales pitch, just a candid assessment of your AI validation posture.
Request a Briefing